David is an accomplished IP trial lawyer who focuses his practice on biologic drug patent and Hatch-Waxman patent litigation. His extensive biologics drug patent litigation experience includes litigating matters relating to Stelara® (ustekinumab), Avastin® (bevacizumab), and Herceptin® (trastuzumab).

In the Hatch-Waxman side of his practice, David represents both patentees and generic filers, guiding them through all phases of litigation. He has handled disputes relating to Imbruvica® (ibrutinib), Xarelto® (rivaroxaban), Suboxone® (buprenorphine naloxone), Pradaxa® (dabigatran etexilate), Ultiva® (remifentanil hydrochloride), Daytrana® (methylphenidate), Dymista® (azelastine HCl/fluticasone propionate), Epaned® (enalapril maleate), and Brisdelle® (paroxetine).

In addition, David has represented a major pharmaceutical company in product liability matters relating to Viread®, Truvada®, Atripla®, and other antiviral medications containing tenofovir disoproxil fumarate (TDF).

David also maintains an active pro bono practice focusing on advocating for LGBTQ+ equality. He has filed administrative complaints under the Federal Tort Claims Act, prepared and filed asylum applications and supporting documentation, and submitted petitions for legal name changes.

Prior to joining Mintz, David was a senior counsel in the Litigation Department’s Life Sciences Group at an international law firm. Earlier, he practiced at another global law firm.

In law school, David served as the lead article editor of the Minnesota Journal of Law, Science & Technology.